3805 OLD EASTON ROAD, DOYLESTOWN, PA
Announces Closing of Oversubscribed $30 Million Private Placement
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD, Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Investor Presentation
Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Reports Third Quarter 2025 Financial Results and Provides a Clinical Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload